Hagop Kantarjian

UNVERIFIED PROFILE

Are you Hagop Kantarjian?   Register this Author

Register author

Hagop Kantarjian

Publications by authors named "Hagop Kantarjian"

Are you Hagop Kantarjian?   Register this Author

100Publications

-Reads

PET-CT in AML-related hemophagocytic lymphohistiocytosis.

Leuk Lymphoma 2018 Jun 28;59(6):1486-1489. Epub 2017 Sep 28.

a Department of Leukemia , The University of Texas, MD Anderson Cancer Center , Houston , TX , USA.

View Article
June 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

J Clin Oncol 2018 Jun 27;36(18):1788-1797. Epub 2018 Apr 27.

Kiyomi Morita, Hagop M. Kantarjian, Feng Wang, Yuanqing Yan, Carlos Bueso-Ramos, Koji Sasaki, Ghayas C. Issa, Sa Wang, Jeffrey Jorgensen, Xingzhi Song, Jianhua Zhang, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Latasha Little, Curtis Gumbs, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Jorge E. Cortes, Tapan Kadia, Elias Jabbour, Guillermo Garcia-Manero, Keyur P. Patel, P. Andrew Futreal, and Koichi Takahash, The University of Texas MD Anderson Cancer Center, Houston, TX; Kiyomi Morita, The University of Tokyo, Tokyo; and Koichi Takahashi, Kyoto University, Kyoto, Japan.

View Article
June 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med 2018 06 2;378(25):2386-2398. Epub 2018 Jun 2.

From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) - both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.); University of Texas Southwestern Medical Center, Dallas (R.H.C.); University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco (G.N.M.), and City of Hope Medical Center, Duarte (A.S.S.) - both in California; University of Colorado School of Medicine, Aurora (D.A.P.); Sarah Cannon Research Institute, Nashville (W.D.); Massachusetts General Hospital Cancer Center (A.T.F.) and Dana-Farber Cancer Institute (R.M.S.), Boston, and Agios Pharmaceuticals, Cambridge (S.C., H.W., V.Z., K.E.Y., S.M.K., H.Y., D.D., B.F., M.G., H.L., S.A., B.W., E.C.A.) - all in Massachusetts; University of Alabama at Birmingham, Birmingham (H.P.E.); Johns Hopkins University, Baltimore (G.T.P.); Washington University School of Medicine, St. Louis (G.L.U.); Mayo Clinic, Jacksonville, FL (J.M.F.); Oregon Health and Science University Knight Cancer Institute, Portland (E.T.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.K.S.); Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Mayo Clinic, Phoenix, AZ (J.L.S.); and Cleveland Clinic, Cleveland (M.A.S.).

View Article
June 2018

Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.

JAMA Oncol 2018 Jun 21. Epub 2018 Jun 21.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston.

View Article
June 2018

Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.

Leukemia 2018 May 22;32(5):1094-1105. Epub 2018 Feb 22.

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article
May 2018

Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.

Cancer 2018 May 6;124(10):2151-2160. Epub 2018 Mar 6.

Adult Bone Marrow Transplant Unit, University Hospitals Bristol, National Health Service Foundation Trust, Bristol, United Kingdom.

View Article
May 2018

L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia.

Clin Lymphoma Myeloma Leuk 2018 May 26;18(5):e191-e195. Epub 2018 Feb 26.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article
May 2018

The importance of greater speed in drug development for advanced malignancies.

Cancer Med 2018 May 30;7(5):1824-1836. Epub 2018 Mar 30.

University of California San Diego Moores Cancer Center, San Diego, California.

View Article
May 2018

SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Clin Lymphoma Myeloma Leuk 2018 May 22. Epub 2018 May 22.

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article
May 2018

The emerging role of immune checkpoint based approaches in AML and MDS.

Leuk Lymphoma 2018 Apr 6;59(4):790-802. Epub 2017 Jul 6.

a Department of Leukemia , The University of Texas M. D. Anderson Cancer Center , Houston , TX , USA.

View Article
April 2018

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.

Leuk Lymphoma 2018 Apr 25;59(4):1012-1015. Epub 2017 Aug 25.

a Department of Leukemia , The University of Texas, MD Anderson Cancer Center , Houston , TX , USA.

View Article
April 2018

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.

Curr Hematol Malig Rep 2018 Apr;13(2):91-99

Department of Leukemia, Unit 428, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article
April 2018

Hepatitis C: When high drug prices preclude patient benefit.

Cancer 2018 Apr 27;124(8):1644-1646. Epub 2018 Feb 27.

Department of Clinical Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
April 2018

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.

Curr Opin Hematol 2018 Mar;25(2):136-145

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article
March 2018

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

Eur J Haematol 2018 Mar 17;100(3):257-263. Epub 2018 Jan 17.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article
March 2018

The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.

CA Cancer J Clin 2018 Mar 16;68(2):153-165. Epub 2018 Jan 16.

Medical Oncologist, Immigrant Health and Cancer Disparities Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article
March 2018

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.

Am J Hematol 2018 Mar;93(3):442-459

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

View Article
March 2018

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

J Hematol Oncol 2018 Mar 15;11(1):42. Epub 2018 Mar 15.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article
March 2018

Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.

Am J Hematol 2018 Feb 31;93(2):286-295. Epub 2017 Oct 31.

Leukemia department, University of Texas, MD Anderson Cancer Center, Houston, Texas.

View Article
February 2018

Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2018 Jan 25;18(1):e19-e25. Epub 2017 Sep 25.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article
January 2018

Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.

Ann Hematol 2018 Jan 15;97(1):109-121. Epub 2017 Nov 15.

Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, 1400 Holcombe Blvd, Unit 428, PO Box 301439, Houston, TX, 77230-1439, USA.

View Article
January 2018

Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

Cancer 2017 Dec 20;123(24):4935-4936. Epub 2017 Oct 20.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
December 2017

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Exp Hematol Oncol 2017 9;6:30. Epub 2017 Nov 9.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 428, Houston, TX 77030 USA.

View Article
November 2017

Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.

Oncotarget 2017 Nov 1;8(60):102150-102160. Epub 2017 Nov 1.

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article
November 2017

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

Future Oncol 2017 Oct 4;13(25):2233-2242. Epub 2017 Aug 4.

Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe BLVD Unit 0428, Houston, TX 77030, USA.

View Article
October 2017

Immunotherapy based approaches in myelofibrosis.

Expert Rev Hematol 2017 10 22;10(10):903-914. Epub 2017 Aug 22.

a MD Anderson Cancer Center , The University of Texas , Houston , TX , USA.

View Article
October 2017

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI-110) in Myeloid Malignancies.

CPT Pharmacometrics Syst Pharmacol 2017 Oct 28;6(10):712-718. Epub 2017 Sep 28.

Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, Maryland, USA.

View Article
October 2017

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.

J Natl Compr Canc Netw 2017 Sep;15(9):1091-1102

From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Moffitt Cancer Center; Massachusetts General Hospital Cancer Center; UC San Diego Moores Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; City of Hope Comprehensive Cancer Center; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Alabama at Birmingham Comprehensive Cancer Center; University of Michigan Comprehensive Cancer Center; University of Washington/Seattle Cancer Care Alliance; Fred & Pamela Buffett Cancer Center; Stanford Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Yale Cancer Center/Smilow Cancer Hospital; Mayo Clinic Cancer Center; University of Colorado Cancer Center; University of Wisconsin Carbone Cancer Center; Memorial Sloan Kettering Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Roswell Park Cancer Institute; and National Comprehensive Cancer Network.

View Article
September 2017

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?

Best Pract Res Clin Haematol 2017 Sep 15;30(3):193-200. Epub 2017 Jun 15.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article
September 2017

FLT3 inhibition in acute myeloid leukaemia.

Lancet Oncol 2017 Aug 26;18(8):988-989. Epub 2017 Jul 26.

Department of Leukemia, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article
August 2017

New Series: SOHO 'State of the Art Updates and Next Questions'.

Clin Lymphoma Myeloma Leuk 2017 Aug;17(8):463

Chair, Scientific Committee, Society of Hematologic Oncology; and, Alexander J. Trotman Professor of Leukemia Research, Associate Director for Translational Research, Associate Chief of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI.

View Article
August 2017

Co-occurrence of -TKD and mutations defines a highly favorable prognostic AML group.

Blood Adv 2017 Aug 17;1(19):1546-1550. Epub 2017 Aug 17.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article
August 2017

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia.

Appl Immunohistochem Mol Morphol 2017 Jul 4. Epub 2017 Jul 4.

Departments of *Leukemia †Hematopathology ‡Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX §AccuGenomics, Wilmington, NC.

View Article
July 2017

Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis.

Clin Lymphoma Myeloma Leuk 2017 07;17S:S105-S110

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO. Electronic address:

View Article
July 2017

Therapy-related myelofibrosis does not appear to exist.

Blood Adv 2017 Jun 26;1(14):863-866. Epub 2017 May 26.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and.

View Article
June 2017

Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.

Blood Adv 2016 Dec 27;1(3):260-264. Epub 2016 Dec 27.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article
December 2016